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Abstract Sphingosine-1-phosphate (Sph-1-P) regulates critical
cellular functions including cell proliferation, di¡erentiation, an-
giogenesis, and cell survival. However, its mechanisms of action
are incompletely understood. Here, we show a novel biological
e¡ect of Sph-1-P: inhibition of acidic sphingomyelinase
(A-SMase) activity in apoptotic bone marrow-derived macro-
phages. A-SMase catalyzes the conversion of sphingomyelin to
ceramides, which are pro-apoptotic. This action of Sph-1-P pre-
vents the accumulation of ceramides and blocks apoptosis,
thereby promoting survival of the macrophages.
& 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Sphingosine-1-phosphate (Sph-1-P) is a bioactive lipid that
controls important biological functions. It was ¢rst described
as a mitogen for cultured ¢broblasts [1] and subsequently has
been implicated in the regulation of other cellular processes
including cell di¡erentiation, migration, angiogenesis and cell
survival [2,3]. There is evidence of dual messenger functions
for Sph-1-P. First, Sph-1-P can be released into the blood
stream upon platelet or mast cell activation, thereupon inter-
acting with speci¢c G protein-coupled receptors of the endo-
thelial di¡erentiation gene family. This action has been asso-
ciated mainly with the regulation of cell migration, neovessel
formation, neurite retraction, or cell survival [2^4]. Second,
Sph-1-P has been shown to act intracellularly as a second
messenger to regulate cell proliferation, suppression of apo-
ptosis, and also cell survival [2,3]. In this regard, activation of
sphingosine kinase and enhanced formation of Sph-1-P was
shown to be induced by platelet-derived growth factor, but
not by epidermal growth factor, leading to activation of the
mitogen-activated protein kinase (MAPK) extracellular regu-
lated kinase 1/2 (ERK1/2) [5]. In addition, Sph-1-P inhibits
c-Jun N-terminal kinase (JNK) activation [6], which is rele-
vant because the balance between ERK and JNK activation
has been implicated in the control of apoptosis [7]. Further-
more, Sph-1-P counteracts the e¡ects of ceramide, which is a
sphingolipid metabolite that inhibits cell growth and induces
apoptosis potently in di¡erent cell types [6,8]. The biological
actions elicited by Sph-1-P involve activation of diverse signal-
ing pathways. For example, e¡ects of Sph-1-P on cytoskeletal
rearrangement and cell motility are mediated by the small
GTPases Rac and Rho, whereas stimulation of cell prolifer-
ation and cell survival by Sph-1-P involves intracellular Ca2þ
mobilization and activation of MAPK, phospholipase D, pro-
tein kinase B (PKB), and transcription factors such as AP-1
[2,3].
We recently found evidence of sphingomyelinase (SMase)
activation and ceramide generation in bone marrow-derived
macrophages (BMDM) induced to undergo apoptosis by
growth factor withdrawal (unpublished work). In the present
study, we present the novel observation that Sph-1-P is a
potent inhibitor of SMase activity and ceramide formation
thereby promoting macrophage survival.
2. Materials and methods
2.1. Materials
RPMI 1640 medium, lysophosphatidic acid (LPA), phenazine me-
thosulfate, and sphingomyelin (from bovine brain) were from Sigma/
Aldrich Canada (Oakville, ON, Canada). De¢ned fetal bovine serum
(FBS) was from Hyclone (Logan, UT, USA). Fisher Scienti¢c
(Edmonton, AB, Canada) supplied 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt
(MTS). C2-ceramide, dihydroC2-ceramide, sphingosine and Sph-1-P
were from Avanti Polar Lipids (Alabaster, AL, USA). [3H]Palmitate
and radiolabelled bovine sphingomyelin (choline-[14C]methyl) were
from Mandel Scienti¢c (Guelph, ON, Canada). ERK1/2 (Thr-202/
Tyr-204) and phospho-PKB antibodies were purchased from New
England BioLabs (Beverly, MA, USA). Antibodies to PKB and cas-
pase-3 proenzyme were from Stressgen (Victoria, BC, Canada). Anti-
bodies to Bcl-XL and active caspase-3 were supplied by BD-Pharmin-
gen (Mississauga, ON, Canada). PD98059, LY294002, and
wortmannin were from Calbiochem products supplied by VWR Can-
lab (Mississauga, ON, Canada).
2.2. Cell culture
Bone marrow macrophages were isolated from femurs of 6^8-week-
old female CD-1 mice as described [9]. Cells were plated for 24 h in
RPMI 1640 medium containing 10% FBS and 10% L-cell conditioned
medium as the source of macrophage colony stimulating factor
(M-CSF) [10]. The non-adherent cells were removed and cultured in
the above medium until about 80% con£uence was reached (5^7
days), for use in the experiments.
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2.3. Cell viability assay
Macrophages were seeded at 25 000 cells/well in 96-well plates and
incubated overnight in RPMI 1640 with 10% FBS and 10% L-cell
conditioned medium as a source of M-CSF. The medium was then
replaced by fresh RPMI 1640 medium with 10% FBS in the presence
or absence of agonists and/or inhibitors as appropriate. Cell viability
was estimated by measuring the rate of reduction of the tetrazolium
dye MTS as described [10].
2.4. Ceramide determination
Radioactivity in ceramide was determined after labeling BMDM
with 5 WCi/ml of [3H]palmitate for 24 h in RPMI 1640 with 10%
FBS and 10% L-cell conditioned medium as the source for M-CSF,
as described [8,11]. The radioactive medium was aspirated, and cells
washed twice with non-radioactive RPMI 1640 containing 10% FBS,
but without M-CSF. The macrophages were then incubated in this
same medium in the absence or in the presence of agonist, as required.
Cells were then washed twice with ice-cold calcium-free phosphate-
bu¡ered saline and scraped into 0.5 ml of methanol. The cells were
washed with a further 0.5 ml of methanol, and the two methanol
samples were combined and mixed with 0.5 ml of chloroform. Lipids
were extracted by separation of phases with a further 0.5 ml of chlo-
roform and 0.9 ml of a solution containing 2 M KCl and 0.2 M
H3PO4. Chloroform phases were dried down under N2 and lipids
were separated by thin-layer chromatography using silica gel 60-
coated glass plates. The plates were developed for 50% of their lengths
with chloroform/methanol/acetic acid (9:1:1, v/v) and then dried.
They were then developed for their full length with petroleum ether,
boiling point 40^60‡C/diethylether/acetic acid (60:40:1, v/v). The po-
sition of ceramides was identi¢ed after staining with I2 vapor by
comparison with authentic standards. Radioactivity was quanti¢ed
by scraping the ceramide spots from the plates by liquid scintillation
counting.
2.5. Measurement of DNA fragmentation
DNA fragmentation was determined using £ow cytometry, as de-
scribed [10].
2.6. SMase assay
The activities of acidic and neutral SMases (A-SMase and
N-SMase, respectively) were determined as described by Liu and Han-
nun [12] using (choline-[14C]methyl) sphingomyelin as the substrate.
SMase activity in permeabilized macrophages was determined in a
similar manner, but in the presence of 20 Wg/ml digitonin [11].
2.7. Western blotting
Macrophages were harvested and lysed in ice-cold homogenization
bu¡er as described [10]. 40^50 Wg of protein from each sample was
loaded and separated by SDS^PAGE, using 10% or 15% separating
gels. Proteins were transferred to nitrocellulose paper and blocked for
1 h with 4% skim milk in Tris-bu¡ered saline (TBS) containing 0.01%
NaN3 and 0.1% Tween 20, and then incubated overnight with the
primary antibody in TBS/0.1% Tween at room temperature. After
three washes with TBS/0.1% Tween 20, membranes were incubated
with horseradish peroxidase-conjugated secondary antibody at 1:5000
dilution for 1 h. Bands were visualized using enhanced chemilumines-
cence, and recorded with a Fluorochem 8000 imaging system (Can-
berra Packard Canada, Mississauga, ON, Canada).
2.8. Statistical analysis
Results are expressed as meansSS.E.M. of three independent ex-
periments performed in triplicate, unless indicated otherwise. Statisti-
cal analysis was done using ANOVA or Student’s t-test as appropri-
ate, with level of signi¢cance set at P6 0.05.
3. Results and discussion
It is generally believed that removal of growth factors from
hemopoietic cells leads to cell death via apoptosis ([13] and
references therein). One well-established experimental model is
BMDM, which typically undergo apoptosis within 24^48 h of
M-CSF withdrawal [10,13]. We chose this model to evaluate
the e¡ects of Sph-1-P on macrophage survival. As shown in
Fig. 1 (upper panel), Sph-1-P signi¢cantly increased macro-
phage viability after M-CSF withdrawal whereas sphingosine
or the structurally related lysophospholipid LPA had no ef-
fect. To evaluate whether the pro-survival e¡ect of Sph-1-P
was due to inhibition of apoptosis or to e¡ects on primary or
secondary necrosis (which also occur under these conditions),
cells were analyzed for DNA fragmentation and caspase-3
activation. After withdrawal of M-CSF for 24 h, 23.7S 5.1%
of cells had DNA fragmentation by £ow cytometry (meanS
S.E.M. of four independent experiments), and this was de-
creased to 7.1 S 3.1% by 30 WM Sph-1-P (P6 0.05). By con-
trast, LPA or sphingosine, at similar concentration, were in-
e¡ective. In agreement with other work [14,15], Sph-1-P also
prevented the activation of caspase-3, which is an e¡ector
protein of apoptosis (Fig. 1, lower panel). Dying cells often
show increased concentrations of ceramides, which are pro-
apoptotic [16,17]. We observed that M-CSF deprivation
caused a marked increase of ceramide levels in macrophages,
and this was inhibited by 30 WM Sph-1-P (Fig. 2, upper pan-
el). Therefore, we hypothesized that Sph-1-P might block cell
Fig. 1. Sph-1-P promotes macrophage survival. Upper panel:
BMDM were seeded at 25U103 cells/well in 96-well plates and incu-
bated in RPMI 1640 with 10% FBS, but without M-CSF, for 30 h
in the absence or in the presence of increasing concentrations of
Sph-1-P (squares), sphingosine (Sph, circles), or LPA (triangles).
Cell viability was determined by the MTS assay as described in Sec-
tion 2. Results are expressed relative to control cells at 0 h. Data
represent meansSS.E.M. of four di¡erent experiments performed in
quadruplicate. Lower panel: BMDM were seeded at 5U106 cells/
100-mm dish and incubated in RPMI 1640 with 10% FBS, but with
or without 10% L-cell conditioned medium (M-CSF) or Sph-1-P (30
WM) for 30 h, as indicated. The levels of the 32-kDa pro-enzyme of
caspase-3 as well as the 17-kDa active fragment were assessed by
immunoblotting as described in Section 2. Results shown are repre-
sentative of three independent experiments.
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death by inhibiting ceramide production. Although ceramides
can be formed by de novo synthesis, one of the major path-
ways for generation of bioactive ceramide is the SMase path-
way [16,17]. Thus, experiments were carried out to determine
whether SMase activation was the cause for the production of
ceramides. This was achieved by measuring A- and N-SMase
activities after M-CSF withdrawal. We found that both A- and
N-SMase activities were stimulated by M-CSF deprivation in
a time-dependent manner, and that nearly all of the SMase
activity (98%) was attributable to the acidic form of the en-
zyme. The extent of SMase activation varied among di¡erent
experiments, but there was consistency in cell responsiveness
for the macrophages of individual preparations. The speci¢c
activities of basal A-SMase and N-SMase were 39.8 S 4.3
(meanSS.E.M., n=12) and 0.9 S 0.1 (meanSS.E.M., n=8)
nmol of substrate converted per hour per milligram of pro-
tein, respectively. Maximal activation of both A- and N-SM-
ases was attained after about 30 h of M-CSF withdrawal
(Fig. 2, lower panel). The N-SMase activity was totally de-
pendent upon Mg2þ ions. Fig. 3 presents the key observation
that Sph-1-P inhibited the activation of A-SMase in intact
cells, thereby blocking the accumulation of ceramides. Sph-
1-P also decreased the activation of N-SMase by about
28S 5% (meanS range of two independent experiments). In-
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Fig. 2. M-CSF withdrawal increases ceramide levels through SMase
activation. Upper panel: BMDM were seeded at 1U106 cells/well in
6-well plates and labeled with 5 WCi/ml of [3H]palmitate as indicated
in Section 2. Cells were then washed to remove unincorporated label
and incubated for 38 h with or without 30 WM Sph-1-P, as indi-
cated. Ceramide was isolated by thin-layer chromatography and
quantitated as described in Section 2. Values are calculated as a per-
centage of the radioactivity present in [3H]ceramide compared with
that in total lipids, and then expressed as the fold stimulation rela-
tive to incubations at 0 h. Results are the meanSS.E.M. of three
independent experiments performed in triplicate. Lower panel:
BMDM were seeded at 1U106 cells/well in 6-well plates and incuba-
ted in RPMI 1640 with 10% FBS for 0^38 h. Acid (squares) and
neutral (circles) SMase activities were determined as indicated in
Section 2. The speci¢c activities of basal A-SMase and N-SMase are
given in the text (Section 3). Results are expressed relative to con-
trol values at 0 h. Data represent meansSS.E.M. of three di¡erent
experiments performed in duplicate.
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Fig. 3. Sph-1-P inhibits A-SMase activation in intact BMDM but
not in cell homogenates. Intact cells (upper panel) were treated as
in Fig. 2 and incubated for 30 h with increasing concentrations of
Sph-1-P, as indicated. Results are calculated relative to control cells
at 0 h and then expressed as meanSS.E.M. of three independent
experiments. Homogenates from cells incubated without M-CSF for
30 h to stimulate A-SMase (lower panel) were treated with increas-
ing concentrations of Sph-1-P, as indicated. Results represent means
SS.E.M. of three independent experiments.
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terestingly, the inhibition of A-SMase activity required cell
integrity as Sph-1-P failed to inhibit SMase activation in cell
homogenates (Fig. 3, lower panel). This observation suggests
that the mechanism of A-SMase inhibition does not involve a
direct physical interaction of Sph-1-P with the enzyme.
Although Sph-1-P can act intracellularly to modify signal
transduction pathways, many of its biological e¡ects when
added exogenously are caused by binding to cell surface re-
ceptors that are coupled to pertussis toxin (PTX)-sensitive
Gi/o proteins [3,18]. To determine if the inhibition of
A-SMase by Sph-1-P was mediated by a receptor of this
kind, BMDM were incubated for 30 h in the presence of
PTX concentrations ranging from 10 to 100 ng/ml. This treat-
ment failed to reverse the inhibitory e¡ect of Sph-1-P on
A-SMase activation. We noted that at concentrations greater
than 100 ng/ml, PTX alone caused inhibition of A-SMase
activity by an undetermined mechanism. Therefore, these
were not used in the experiments. The possible implication
of GTP-binding proteins in A-SMase activation was investi-
gated further by treating permeabilized macrophages with
GTPQS or GDPLS, which are non-hydrolyzable analogues of
GTP and GDP, respectively. Incubation of permeabilized
BMDM with concentrations of these nucleotides of up to
150 WM for various times (up to 60 min) did not alter
A-SMase activity (data not shown). However, 25 WM GTPQS
stimulated phospholipase D in rat ¢broblasts under similar
conditions [11]. Taken together, these results indicate that
A-SMase activation by M-CSF withdrawal and the inhibitory
e¡ect of Sph-1-P on A-SMase activation are independent of
GTP-binding proteins. In addition, A-SMase activation was
independent of cAMP, as treatment with the adenylyl cyclase-
activating agent forskolin, at concentrations shown to elevate
cAMP, did not alter A-SMase activity in the macrophages
(data not shown). These data are in agreement with previous
studies suggesting that the cytoprotective e¡ects of Sph-1-P
are receptor-independent events [3].
It has been shown that Sph-1-P can activate ERK1/ERK2
or phosphatidylinositol 3-kinase (PI3-K)/PKB in di¡erent cell
types [19^21]. In a previous study, we demonstrated that acti-
vation of the PI3-K/PKB pathway but not MAPK was re-
quired for the anti-apoptotic e¡ect of oxidized low density
lipoprotein in BMDM [10]. In the present work we found
that Sph-1-P preserves PKB phosphorylation after M-CSF
withdrawal (Fig. 4, upper panel). In addition, expression of
anti-apoptotic Bcl-XL, which is regulated by PI3-K, was also
decreased by M-CSF withdrawal, and Sph-1-P partially re-
stores this (Fig. 4, lower panel). To determine whether the
PI3-K pathway was involved in the attenuation of apoptosis
PPKB
PKB
+MCSF -MCSF +SPP +SPP +SPP
+Cer +H2Cer
+SPP
-MCSF+MCSF-MCSF
BcIXL
Fig. 4. Sph-1-P-mediated macrophage survival involves maintenance of PKB phosphorylation and increases Bcl-XL levels. BMDM were seeded
as indicated in Fig. 2. In the upper panel, cells in the ¢rst lane were incubated for 30 h with: 10% L-cell conditioned medium as source of
M-CSF; all other lanes were without M-CSF with or without 30 WM Sph-1-P (SPP); 30 WM Sph-1-P plus 50 WM C2-ceramide (SPP+Cer); or
30 WM Sph-1-P plus 50 WM dihydro-C2-ceramide (SPP+H2Cer). Phospho-PKB (PPKB) and PKB levels were assessed by immunoblotting as de-
scribed in Section 2. In the lower panel, cells were incubated without M-CSF, with 10% L-conditioned medium (M-CSF), or with 30 WM Sph-
1-P (SPP) in the absence of M-CSF. Bcl-XL levels were assessed by immunoblotting as described in Section 2. Similar results were obtained in
each of two replicate experiments.
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Fig. 5. PI3-K inhibitors block Sph-1-P-mediated macrophage surviv-
al. BMDM were seeded as indicated in Fig. 1. They were then pre-
incubated with vehicle, or with the MEK inhibitor PD98059 (PD)
at 10 WM, or with the PI3-K inhibitors LY294002 (LY) at 5 WM
and wortmannin (W) at 100 nM for 1 h before treatment with 30
WM Sph-1-P (SPP), as indicated. CTR indicates conditions in the
absence of agonist or inhibitors. Macrophage viability was measured
after 30 h by the MTS assay. Results are expressed relative to con-
trol cells at 0 h. Data represent meansSS.E.M. of four independent
experiments performed in quadruplicate (**P6 0.01, CTR vs. SPP
value, and SPP value vs. SPP+LY value; *P6 0.05, SPP value vs.
SPP+W value).
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by Sph-1-P, we tested the e¡ects of selective inhibitors on cell
survival in the presence of Sph-1-P. As shown in Fig. 5, the
PI3-K inhibitors LY294002 and wortmannin blocked the ef-
fect of Sph-1-P on macrophage survival, whereas the MAPK/
ERK kinase (MEK) inhibitor PD98059 did not, even though
it blocked ERK1/ERK2 phosphorylation by immunoblot
analysis. This ¢nding is similar to our previous study of the
anti-apoptotic e¡ect of oxidized low density lipoprotein in
BMDM, which was also blocked by PI3-K inhibitors but
not MEK inhibitors [10]. These results suggest that the PI3-
K/PKB signaling cascade, but not ERK1/ERK2, is involved
in Sph-1-P-mediated macrophage survival. In agreement with
other work [22,23] PKB phosphorylation was inhibited by the
cell-permeable C2-ceramide (N-acetylsphingosine), but not by
its biologically inactive analogue N-dihydro-C2-ceramide
(Fig. 4, upper panel). Therefore, the inhibition of SMase ac-
tivity and the subsequent decrease in ceramide levels by Sph-
1-P could be important for maintaining PKB activation and
macrophage survival. In this regard, we found that C2-ceram-
ide, but not dihydro-C2-ceramide, blocked Sph-1-P-induced
macrophage survival (Fig. 6), thereby emphasizing the impor-
tance for cells to maintain an appropriate balance in the levels
of intracellular Sph-1-P and ceramides. These data are in
agreement with our previous work showing that Sph-1-P
and ceramides are antagonistic signals [8], and with that of
Cuvillier et al. [6] who demonstrated that Sph-1-P blocks cer-
amide-induced apoptosis.
In conclusion, here we demonstrate for the ¢rst time that
Sph-1-P inhibits SMase activity and the subsequent genera-
tion of ceramides, thereby promoting cell survival.
Acknowledgements: This work was supported by Grants MT8630
from CIHR, SAF-2002-03184 from the Ministerio de Ciencia y Tec-
nolog|¤a (Spain), and by a visiting scientist award to A.G.M. from the
Geraldine Dow Ferry Endowment for IBD Research.
References
[1] Zhang, H., Desai, N.N., Olivera, S., Seki, T., Brooker, G. and
Spiegel, S. (1991) J. Cell Biol. 114, 155^167.
[2] Payne, S.G., Milstien, S. and Spiegel, S. (2002) FEBS Lett. 531,
54^57.
[3] Spiegel, S. and Milstien, S. (2002) J. Biol. Chem. 277, 25851^
25854.
[4] Ancellin, N., Colmon, C., Su, J., Li, Q., Mittereder, R., Chae,
S-S., Stefansson, S., Liau, G. and Hla, T. (2002) J. Biol. Chem.
277, 6667^6675.
[5] Olivera, A. and Spiegel, S. (1993) Nature 365, 557^560.
[6] Cuvillier, O., Pirianov, G., Kleuser, B., Vanek, P.G., Coso, O.A.,
Gutkind, J.S. and Spiegel, S. (1996) Nature 381, 800^803.
[7] Xia, Z., Dickens, M., Raingeaud, J., Davis, R.J. and Greenberg,
M.E. (1995) Science 270, 1326^1331.
[8] Go¤mez-Mun‹oz, A., Waggoner, D.W., O’Brien, L. and Brindley,
D.N. (1995) J. Biol. Chem. 270, 26318^26325.
[9] Hamilton, J.A., Myers, D., Jessup, W., Cochrane, F., Byrne, R.,
Whitty, G. and Moss, S. (1999) Arterioscler. Thromb. Vasc. Biol.
19, 98^105.
[10] Hundal, R., Salh, B.J., Schrader, J.W., Go¤mez-Mun‹oz, A., Du-
ronio, V. and Steinbrecher, U.P. (2001) J. Lipid Res. 42, 1483^
1491.
[11] Go¤mez-Mun‹oz, A., Martin, A., O’Brien, L. and Brindley, D.N.
(1994) J. Biol. Chem. 269, 8937^8943.
[12] Liu, B. and Hannun, Y.A. (1999) Methods Enzymol. 311, 164^
168.
[13] Jaworowski, A., Wilson, N.J., Christy, E., Byrne, R. and Ham-
ilton, J.A. (1999) J. Biol. Chem. 274, 15127^15133.
[14] Cuvillier, O., Rosenthal, D.S., Smulson, M.E. and Spiegel, S.
(1998) J. Biol. Chem. 274, 2910^2916.
[15] Olivera, A., Kohama, T., Edsall, L., Nava, V., Cuvillier, O.,
Poulton, S. and Spiegel, S. (1999) J. Cell Biol. 147, 545^558.
[16] Hannun, Y.A. (1994) J. Biol. Chem. 269, 3125^3128.
[17] Kolesnick, R. and Golde, D.W. (1994) Cell 77, 325^328.
[18] Wang, F., Van Brocklyn, J.R., Hobson, J.P., Movafagh, S., Zu-
kowska-Grojec, Z., Milstien, S. and Spiegel, S. (1999) J. Biol.
Chem. 274, 35343^35350.
[19] Morales-Ruiz, M., Menq-Jer, L., Zo«lner, S., Gratton, J-P., Scot-
land, R., Shiojima, I., Walsh, K., Hla, T. and Sessa, W.C. (2001)
J. Biol. Chem. 276, 19672^19677.
[20] Pe¤bay, A., Toutant, M., Pre¤mont, J., Calvo, C.-F., Venance, L.,
Cordier, J., Glowinski, J. and Tence¤, M. (2001) Eur. J. Neurosci.
13, 2067^2076.
[21] Zondag, G.C., Postma, F.R., van Etten, I., Verlaan, I. and Moo-
lenaar, W.H. (1998) Biochem. J. 330, 605^609.
[22] Schubert, K.M., Scheid, M.P. and Duronio, V. (2000) J. Biol.
Chem. 275, 13330^13335.
[23] Bourbon, N.A., Sandirasegarane, L. and Kester, M. (2002)
J. Biol. Chem. 277, 3286^3292.
0
20
40
60
80
100
Ce
ll v
ia
bi
lity
 (%
)
CT
R
SP
P Ce
r
SP
P+
Ce
r
H2
Ce
r
SP
P+
H2
Ce
r
* *
*
*
Fig. 6. C2-ceramide prevents Sph-1-P-mediated macrophage survival.
BMDM were seeded as indicated in Fig. 1. They were then preincu-
bated with 50 WM C2-ceramide (Cer) or 50 WM dihydro-C2-ceramide
(H2Cer) for 1 h before treatment with 30 WM Sph-1-P (SPP), as in-
dicated. CTR indicates conditions in the absence of any addition.
Macrophage viability was measured after 30 h by the MTS assay.
Results are expressed relative to control cells at 0 h. Data represent
meansSS.E.M. of three independent experiments performed in qua-
druplicate (**P6 0.01, CTR vs. SPP value; *P6 0.05, CTR vs. Cer
value, and SPP value vs. SPP+Cer value).
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